Remedium Capital Partners, LLC

CIK 0002104501 · WEST PALM BEACH, FL · Quarter end: 2026-06-30 · Filed on: 2026-08-07 · Open the SEC source ↗

Remedium Capital Partners, LLC reported 6 positions worth $451.6M as of June 30, 2026 (13F filed August 7, 2026). Largest holding: ORKA (33.0%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$451.6M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

6 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	ORKA	Oruka Therapeutics Inc	SH	$149.0M	32.99%	1,565,661	—	—
▸ 2	SYRE	Spyre Therapeutics Inc	SH	$130.0M	28.78%	1,464,169	—	—
▸ 3	03770N101	Apogee Therapeutics Inc	SH	$77.9M	17.24%	586,691	—	—
▸ 4	36322Q206	Damora Therapeutics Inc	SH	$53.2M	11.78%	2,045,473	—	—
▸ 5	JBIO	Jade Biosciences Inc	SH	$35.1M	7.76%	1,577,750	—	—
▸ 6	CBIO	Crescent Biopharma Inc	SH	$6.5M	1.44%	361,250	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Remedium Capital Partners, LLC hold as of Q2 2026?

Remedium Capital Partners, LLC reported 6 positions worth $451.6M in its Q2 2026 13F filing. Largest positions: ORKA (33.0%), SYRE (28.8%), Apogee Therapeutics Inc (17.2%), Damora Therapeutics Inc (11.8%) and JBIO (7.8%).

What did Remedium Capital Partners, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Remedium Capital Partners, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.